Podcasts about nirsevimab

Maternal RSV vaccines and infant nirsevimab led to major drops in hospitalizations among infants ≤7 months, especially those ≤2 months old. The CDC's 2025 nPEP guidelines stress starting HIV prevention within 72 hours of exposure, with rapid testing and follow-up care. Treatment should begin without delay, and patients at ongoing risk should transition to PrEP. Surgical site infections after colorectal surgery have increased 21% since 2019, highlighting the need to strengthen infection control.

On episode #80 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 4/24/25 – 5/7/25. Hosts: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Incidence and Timing of Epstein–Barr Virus Whole Blood DNAemia in Epstein–Barr Virus-Mismatched Adult and Pediatric Solid Organ Transplant Recipients (Transplant Infectious Disease) Infant Respiratory Syncytial Virus Immunization Coverage in the Vaccine Safety Datalink: 2023–2024 (American Academy of Pediatrics) Impact of Nirsevimab on RSV and Non-RSV Severe Respiratory Infections in Hospitalized Infants (Influenza and other respiratory viruses) Hospital admissions of respiratory infections in infants plungewith nirsevimab RSV antibody (CIDRAP) Time to antiviral treatment in mild–moderate COVID-19 in the emergency department (Internal and Emergency Medicine) Delays in COVID antiviral receipt raised risk of poor outcomes after ED visits by 18%, data suggest (CIDRAP) Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV (MMWR) Bacterial Validation and clinical implementation of cerebrospinal fluid C-reactive protein for the diagnosis of bacterial meningitis (LANCET: Regional Health) Bridging to transplant: TDM-Guided Outpatient Dalbavancin Therapy in Chronic Granulomatous Disease with deep-seeded Inoperable Abscesses over 11 Months (OFID) Nitrites for Urinary Tract Infection—Time to Say Goodbye? (JAMA: Internal Medicine) Fungal The Last of US Season 2 (YouTube) High Mortality and Associated Risk Factors in Kidney Transplant Recipients with Cryptococcosis – A Nationwide Cohort Study Over a Decade Using USRDS Data (OFID) Use of Dog Serologic Data for Improved Understanding of Coccidioidomycosis (JID) Parasitic Performance of a novel P. falciparum rapid diagnostic test in areas of widespread hrp2/3 gene deletion (CID) Prevalence of Anopheles stephensi in the Horn of Africa: a systematic review and meta-analysis (BMC Infectious Diseases) Raising awareness of Demodex mites: a neglected cause of skin disease (Infection) Miscellaneous Scientific Integrity Under Threat: The Role of the IDSA, PIDS, and SHEA Journals in an Evolving Political Landscape (CID) Reasoning on Rounds Volume 2: a Framework for Teaching Management Reasoning in the Inpatient Setting (Journal of General Internal Medicine) Billing for and documentation of provider-to-provider interprofessional consults in infectious diseases (Journal of the Pediatric Infectious Diseases Society) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

David Liew talks to Linny Phuong, paediatric infectious diseases physician, about changes to prevention and management of respiratory syncytial virus (RSV). They discuss how RSV infections affect communities in Australia, high-risk groups to watch out for, and when to test for RSV. Linny also outlines available RSV immunisations for different populations. Read the full article by Linny and her co-author, David Foley, in Australian Prescriber.

In his weekly clinical update, Dr. Griffin with Vincent Racaniello bemoan the attack on science within the US, salt water controls for vaccines, return to 1938 technology for flu vaccines, mRNA vaccines as “bioweapons”, rise in pertussis, benefits of the shingles vaccine and reduced dementia occurrence, and growing measles outbreak globally before Dr. Griffin reviews recent statistics on RSV, influenza and SARS-CoV-2 infections, the WasterwaterScan dashboard, the May 22 VRBPAC COVID-19 vaccine,  meeting, where to find PEMGARDA, return to antibiotic treatment for respiratory viral diseases, provides information for Columbia University Irving Medical Center's long COVID treatment center, where to go for answers to your long COVID questions and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Saline placebo control testing for new vaccines….not good chemistry! (Washington Post) 1940s innovation: HHS, NIH Launch Next-Generation Universal Vaccine Platform for Pandemic-Prone Viruses(US Department of Health and Human Services) WHAT! Minnesota Bill Against Vaccines Promotes Disinformation (Medscape Medical News) ) Guns= fine….mRNA =mRNA Bioweapons Prohibition Act; mRNA injections and products designated as weapons of mass destruction, and mRNA injections and products prohibited. (Minnesota Legislature) Bioweapons of massive destruction mNRA not bombs or drones….but mRNA! (Minnesota Legislature) 2024 Provisional pertussis surveillance report (CDC) Pertussis cases by year 1922-2023 (CDC: Whooping cough (pertussis)) Deaths by pertussis: 6 children under a year old (CDC) Pertussis (WHO) Symptoms of pertussis (CDC Whooping Cough (Pertussis) With whooping cough cases on the rise, a doctor explains how to protect yourself and others (CNN) Live zoster vaccination and cardiovascular outcomes (European Heath Journal) Shingles vaccine recipients see lower cardiac event risk (CIDRAP) H5 Bird Flu: Current Situation (CDC: Avian Influenza Bird flu) Measles cases and outbreaks (CDC Rubeola) Measles 800 in Texas…. (Texas Health and Human Services) 2025 Measles outbreak guidance (New Mexico Health) Measles and rubella weekly monitoring report: (Government of Canada) Measles vaccine recommendations from NYP (jpg)  Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Measles (CDC: Measles Rubeola) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) Respiratory virus activity levels (CDC Respiratory Illnesses) CDC reports 216 child deaths this flu season (AP News) Weekly surveillance report: clift notes (CDC FluView) FDA-CDC-DOD: 2025-2046 influenza vaccine composition (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Impact of Nirsevimab on RSV and Non-RSV Severe Respiratory Infections in Hospitalized Infants (Influenza and other respiratory viruses) Hospital admissions of respiratory infections in infants plunge with nirsevimab RSV antibody(CIDRAP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Early effectiveness of the BNT162b2 KP.2 vaccine against COVID-19 in the US Veterans Affairs Healthcare System (Nature Commications) Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States (CDC: COVID-19) COVID-19 vaccine VRBPAC May 22 (FDA) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Infectious Disease Society guidelines for treatment and management (ID Society) Time to antiviral treatment in mild–moderate COVID-19 in the emergency department(Internal and Emergency Medicine) Delays in COVID antiviral receipt raised risk of poor outcomes after ED visits by 18%, data suggest(CIDRAP) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC) Managing healthcare staffing shortages (CDC) Virus = Bacteria ? National Trends in Antibiotic Prescribing for Adults Hospitalized With Coronavirus Disease 2019 and Other Viral Respiratory Infections (OFID) Steroids, dexamethasone at the right time (OFD) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Short and long-term trajectories of the post COVID-19 condition (BMJ Infectious Diseases) Prevalence of Persistent Cardiovascular and Pulmonary Abnormalities on PET/MRI and DECT Imaging in Long COVID Patients (Journal of Nuclear Medicine) Long-COVID patients show signs of inflammation on PET/ MRI scans(CIDRAP) Reaching out to US house representative Letters read on TWiV 1216 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Episode 188: RSV Management and PreventionDr. Sandhu and future Dr. Mohamed summarize the management of RSV and describe how to prevent it with chemoprophylaxis and vaccines. Dr Arreaza adds some comments about RSV vaccines.Written by Abdolhakim Mohamed, MSIV, Ross University School of Medicine. Comments by Ranbir Sandhu, MD, and Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.What is RSV? -The Respiratory syncytial Virus (RSV) is an enveloped, negative-sense, single-stranded RNA virus of the Orthopneumovirus genus within the Pneumoviridae family. -RSV is a major cause of acute respiratory tract infections, particularly bronchiolitis and pneumonia, in infants and young children, and it also significantly affects older adults and immunocompromised individuals. -RSV infections cause an estimated 58,000–80,000 hospitalizations among children younger than 5 years and 60,000–160,000 hospitalizations among adults older than 65 years each year.-RSV is highly contagious and spreads through respiratory droplets and direct contact with contaminated surfaces. The virus typically causes seasonal epidemics, peaking in the winter months in temperate climates and during the rainy season in tropical regions. -Virtually all children are infected with RSV by the age of two, and reinfections can occur throughout life, often with milder symptoms.-Per the 2014 Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis, from the American Academy of Pediatrics, the most common etiology of bronchiolitis is RSV. -About 97% of children are infected with RSV in the first 2 years of life, about 40% will experience lower respiratory tract infection during the initial infection. Other viruses that cause bronchiolitis include human rhinovirus, human metapneumovirus, influenza, adenovirus, coronavirus, and parainfluenza viruses.When is RSV season?-Classically, the highest incidence of infection occurs between December and March in North America. Per CDC, there were typical prepandemic RSV season patterns, but the COVID-19 pandemic disrupted RSV seasonality during 2020–2022. -Before we dive into the seasonality patterns, for context, in order to describe RSV seasonality in the US, data was gathered and analyzed from polymerase chain reaction (PCR) test results reported to the National Respiratory and Enteric Virus Surveillance System (NREVSS) during July 2017–February 2023. -Seasonal RSV epidemics were defined as the weeks during which the percentage of PCR test results that were positive for RSV was ≥3%. Per 2017–2020 data, RSV epidemics in the United States typically follow seasonal patterns, that began in October, peaked in December or January, and ended in April. -However, during 2020–21, the typical winter RSV epidemic did not occur. The 2021–22 season began in May, peaked in July, and ended in January. -The 2022–23 season started (June) and peaked (November) later than the 2021–22 season, but earlier than prepandemic seasons. CDC notes that the timing of the 2022–23 season suggests that seasonal patterns are returning toward those observed in prepandemic years, however, warn that clinicians should be aware that off-season RSV circulation might continue.Treatment of RSVSome key points of the 2014 pediatric guidelines from the American Academy of Pediatrics.-AAP strongly do not recommend beta agonists or steroids for viral associated bronchiolitis because of no significant improved outcomes. “Clinicians should not administer albuterol (or salbutamol) to infants and children with a diagnosis of bronchiolitis (Evidence Quality: B; Recommendation Strength: Strong Recommendation).”-Epinephrine is not recommended for infants and children with a diagnosis of bronchiolitis (Evidence Quality: B; Recommendation Strength: Strong Recommendation).-Nebulized hypertonic saline should not be administered to infants with a diagnosis of bronchiolitis in the emergency department (Evidence Quality: B; Recommendation Strength: Moderate Recommendation), but hypertonic saline may be administered when they are hospitalized (Evidence Quality: B; Recommendation Strength: Weak Recommendation [based on randomized controlled trials with inconsistent findings]).-Chest physiotherapy should not be used in infants and children with a diagnosis of bronchiolitis (Evidence Quality: B; Recommendation Strength: Moderate Recommendation).-Antibiotics should not be administered in bronchiolitis unless there is a concomitant bacterial infection, or a strong suspicion of one (Evidence Quality: B; Recommendation Strength: Strong Recommendation).-Oxygen therapy may not be administered if the oxyhemoglobin saturation exceeds 90% in infants and children with a diagnosis of bronchiolitis (Evidence Quality: D; Recommendation Strength: Weak Recommendation [based on low level evidence and reasoning from first principles]).-Clinicians should administer nasogastric or intravenous fluids for infants with a diagnosis of bronchiolitis who cannot maintain hydration orally (Evidence Quality: X; Recommendation Strength: Strong Recommendation).How do we prevent RSV?Infant Immuno-prophylaxis:A clinical trial in 2022 demonstrated that a single injection of nirsevimab (Beyfortus®), administered before the RSV season, protected healthy late-preterm and term infants from RSV-associated lower respiratory tract that required medical treatment. Nirsevimab is a monoclonal antibody to the RSV fusion protein that has an extended half-life.Additionally, on August 3, 2023, the Advisory Committee on Immunization Practices (ACIP) recommended nirsevimab for all infants younger than 8 months who are born during or entering their first RSV season and for infants and children between 8-19 months who are at increased risk for severe RSV disease and are entering their second RSV season. On the basis of pre-COVID-19 pandemic patterns, nirsevimab could be administered in most of the continental United States from October through the end of March.Maternal Vaccination: The CDC recommends the administration of the RSVPreF vaccine to pregnant women between 32 0/7 and 36 6/7 weeks of gestation. This vaccination aims to reduce the risk of RSV-associated lower respiratory tract infection in infants during the first 6 months of life.At this time, if a pregnant woman has already received a maternal RSV vaccine during any previous pregnancy, CDC does not recommend another dose of RSV vaccine during subsequent pregnancies.Older individuals: -Each year in the U.S., it is estimated that between 60,000 and 160,000 older adults are hospitalized and between 6,000 and 10,000 die due to RSV infection-ABRYSVO's approval will help offer older adults protection in the RSV season.-On June 26, 2024, ACIP voted to give these recommendations: all adults older than 75 years and adults between 60–74 years who are at increased risk for severe RSV disease should receive a single dose of RSV vaccine (Abrysvo®).Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:Hamid S, Winn A, Parikh R, et al. Seasonality of Respiratory Syncytial Virus — United States, 2017–2023. MMWR Morb Mortal Wkly Rep 2023;72:355–361. DOI: http://dx.doi.org/10.15585/mmwr.mm7214a1Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, Wählby Hamrén U, Mankad VS, Ren P, Takas T, Abram ME, Leach A, Griffin MP, Villafana T; MELODY Study Group. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N Engl J Med. 2022 Mar 3;386(9):837-846. doi: 10.1056/NEJMoa2110275. PMID: 35235726.Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, Johnson DW, Light MJ, Maraqa NF, Mendonca EA, Phelan KJ, Zorc JJ, Stanko-Lopp D, Brown MA, Nathanson I, Rosenblum E, Sayles S 3rd, Hernandez-Cancio S; American Academy of Pediatrics. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014 Nov;134(5):e1474-502. doi: 10.1542/peds.2014-2742. Erratum in: Pediatrics. 2015 Oct;136(4):782. doi: 10.1542/peds.2015-2862. PMID: 25349312.CDC, per their published article Seasonality of Respiratory Syncytial Virus — United States for 2017–2023, in the United StatesWhat U.S. Obstetricians Need to Know About Respiratory Syncytial Virus.Debessai H, Jones JM, Meaney-Delman D, Rasmussen SA. Obstetrics and Gynecology. 2024;143(3):e54-e62. doi:10.1097/AOG.0000000000005492.Maternal Respiratory Syncytial Virus Vaccination and Receipt of Respiratory Syncytial Virus Antibody (Nirsevimab) by Infants Aged

La subsecretaria Albagli remarcó la importancia de acceder al Nirsevimab, vacuna gratuita contra el sincicial: "El 2024 no tuvimos ninguna muerte".

Understanding RSV and the Impact of NursivMab ImmunizationIn this week's episode, Sheena discusses Respiratory Syncytial Virus (RSV) and provides an update on the current RSV season. She explains the effects of Nirsevimab, the new RSV immunisation introduced through a Pathfinder program for babies born between September 1st and February 28th. She also reads a letter she wrote to Dr. Colm Henry and Minister Stephen Donnelly, urging them to extend the immunization to more babies. She provides insights into how RSV affects different age groups, the success of the Pathfinder program, and encourages listeners to advocate for better immunisation policies. She ends by offering advice for parents of August-born babies on how to reduce their child's risk of contracting RSV.00:00 Introduction to This Week's Episode01:23 Understanding RSV: Symptoms and Risks02:49 NursivMab: The New RSV Immunization05:18 Pathfinder Programme: Impact and Analysis12:24 Addressing Concerns and Future Steps17:38 Conclusion and Call to ActionSeason 10 Partnership – Salin Plus (available here!)I am so thrilled to be partnering with Salin plus This 100% natural salt therapy device is suitable for both adults and children! Tune in to learn more!Support this PodcastSimply following and reviewing this podcast can make a huge difference! If you enjoy this episode I would be so grateful if you could follow or subscribe to the show!#handfootandmouthdisease #handfootandmouth #irishhealth #irishhealthcare #pharmacist #patientadvocate #pharmacyireland #pharmacist #healthpodcast Hosted on Acast. See acast.com/privacy for more information.

Send us a message with this link, we would love to hear from you. Standard message rates may apply.Respiratory syncytial virus (RSV) is a common respiratory virus that can be dangerous for infants. This episode of Your Checkup provides essential information about RSV, exploring new prevention methods like the monoclonal antibody nirsevimab and the maternal RSV vaccine. We discuss how they work, who should consider them, and their safety profiles. Tune in to learn how to safeguard your baby from this potentially serious virus.Support the showProduction and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

Un nouvel épisode du Pharmascope, à saveur pédiatrique, est disponible! Dans ce 144e épisode, Nicolas, Isabelle, Olivier et une célèbre invitée discutent du virus respiratoire syncytial et de nouveaux outils pour le combattre.  Les objectifs pour cet épisode sont les suivants: Expliquer les manifestations cliniques et les facteurs de risque du VRS. Discuter des avantages et des désavantages du nirsévimab. Examiner les études-clés publiées récemment sur le nirsévimab. Ressources pertinentes en lien avec l'épisode  Li Y et coll. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022 May 28;399(10340):2047-2064. Phijffer EW et coll.. Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes. Cochrane Database Syst Rev. 2024 May 2;5(5):CD015134. Protocole d'immunisation du Québec. Griffin MP et coll. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N Engl J Med. 2020 Jul 30;383(5):415-425. Hammitt LL et coll. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N Engl J Med. 2022 Mar 3;386(9):837-846. Drysdale SB et coll. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants. N Engl J Med. 2023 Dec 28;389(26):2425-2435. Domachowske J et coll. Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity. N Engl J Med. 2022 Mar 3;386(9):892-894. Simões EAF et coll. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023 Mar;7(3):180-189.

Comprehensive Guide to the New RSV Immunisation for ParentsIn this detailed episode, I provide an in-depth exploration of the new RSV immunisation, focusing on its importance, safety, and effectiveness. The discussion covers the basics and risks of Respiratory Syncytial Virus (RSV), the introduction and benefits of the Nirsevimab vaccine, and potential side effects. The episode compares Nirsevimab with the older Palivizumab, highlighting its superior efficacy in reducing hospitalisations and ICU admissions. It also addresses eligibility guidelines, the vaccination process, accessibility through government programs, and specific advice for parents, especially those with infants born from September 1st. I reassures parents with real-world success stories, clarify misconceptions, and provide practical tips on preventing RSV through hygiene. The episode aims to equip parents with reliable information to protect their children effectively.00:00 Introduction to RSV Immunisation00:46 Background on RSV and Its Impact02:45 RSV Symptoms and Risks05:16 Parental Guidance for RSV Care07:35 Healthcare System Strain Due to RSV10:34 Introduction to RSV Immunisation11:05 Understanding Monoclonal Antibodies12:16 History and Safety of RSV Antibodies13:19 Nobel Prize-Winning Technology13:30 Challenges with Palivizumab14:11 Introducing Nersivumab15:06 Effectiveness and Safety of Nersivumab17:49 Real-World Data and Results19:22 Eligibility and Administration22:28 Addressing Common Questions26:35 Preventing RSV: Practical TipsSeason 10 Partnership– Salin Plus (available here!)I am so thrilled to be partnering with Salin plus This 100% natural salt therapy device is suitable for both adults and children! Tune in to learn more!Support this PodcastSimply following and reviewing this podcast can make a huge difference! If you enjoy this episode I would be so grateful if you could follow or subscribe to the show! Hosted on Acast. See acast.com/privacy for more information.

With kids back in school, pediatric viral illnesses are revving their engines. It seems we have returned to normal seasonality for viral disease after the coronavirus pandemic. Top of mind with the arrival of fall is respiratory syncytial virus (RSV). We know how quickly the onset of RSV season can take over our waiting rooms.   Last year, two important developments occurred that could change the course of RSV prevention: the FDA approval of a maternal vaccine and a monoclonal antibody for infants. Far too few mothers and infants benefitted from these treatments during last year's respiratory season, but now we've had a year to prepare to do better. Joining us to discuss this hot topic are two expert pediatricians. Sean O'Leary, MD, is an Infectious Disease Physician at Children's Hospital Colorado, a Professor of Pediatrics at the University of Colorado School of Medicine and is the chair of the American Academy of Pediatrics Committee on Infectious Diseases, also known as the Red Book Committee. Matt Dorighi specializes in pediatrics at Cherry Creek Pediatrics. He is currently chair of the Pediatric Care Network, the largest clinically integrated network for children in the state of Colorado.   Some highlights from this episode include:  Guidelines for Nirsevimab and the maternal vaccine  Why availability will not be a barrier this respiratory season  How practices can combat vaccine hesitancy  For more information on Children's Colorado, visit: childrenscolorado.org. 

In his weekly clinical update, Dr. Griffin discusses expanded use of the RSV vaccine by GSK, how the youngest member of the MicrobeTV family was hospitalized with RSV, why we are seeing more RSV infections than before the pandemic and how administration of monoclonal antibody therapy does not prevent infection but disease, before reviewing the weekly US COVID update, how SARS-CoV-2 affects neurodevelopment of the fetus and probability of preeclampsia, if giving Paxlovid prevents long COVID, and FDA recommends switching from the XBB.1.5 variant to JN.1 for fall COVID-19 vaccine formulations. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Young “Immune” co-host with RSV (YouTube) RSV on Immune (MicrobeTV) More children hospitalized with RSV after pandemic than before (Pediatrics) France supports Nirsevimab for RSV (Influenza and other respiratory viruses) Protects against disease not infection Nirsevimab (CIDRAP) TWiV tells it likes it is: protects against disease NOT infection (TWiV 695) RSV vaccine access expanded 50-59 (CIDRAP) GSK RSV vaccine expanded use for high risk 50-year olds (GSK) COVID-19 deaths COVID-19 national trend Neurodevelopmental delay in children whose mothers exposed to SARS-CoV-2 (Scientific Reports) Preeclampsia associated with SARS-CoV-2 infection (Journal of Maternal-Fetal & Neonatal Medicine) Effectiveness of nirmatelvir/ritonavir in children and adolescents (Nat Comm) JN.1 for fall COVID-19 boosters (FDA) COVID-19 vaccine booster switch (CIDRAP) EUA for pemgarda (FDA) Infusion centers near you! (pemgarda.com) CDC quarantine guidelines (CDC) Early phase of SARS-CoV-2 infection (COVID.gov) NIH COVID-19 treatment guidelines (NIH) Infectious Disease Society guidelines for treatment and management (IDSociety) Drug interaction checker (University of Liverpool) Molnupiravir safety and efficiacy (JMV) Convalescent plasma recommendations for immunocompromised (ID Society) Updated respiratory virus guidelines (CDC) What to do when your healthcare provider is infected with SARS-CoV-2 (CDC) Managing healthcare staff shortages (CDC) Steroids, dexamethasone at the right time (OFID) Anticoagulation guidelines (hematology.org) Long COVID evidence based review TWiV shout out (TWiV 1088) Nirmatrelvir-ritonavir prevents long COVID-19? (JAMA Medicine) Contribute to our Floating Doctors fundraiser Letters read on TWiV 1122 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

Reference:  Drysdale SB et al. Nirsevimab for Prevention of Hospitalizations due to RSV in Infants. N Engl J Med. 2023 Date: March 29, 2024 Guest Skeptic: Dr. Michael Cosimini is a pediatrician in Portland Oregon. He is the designer of Empiric Game, a medical editor and contributor to Pediatrics Reviews and Perspectives (PedsRAP) and the […] The post SGEM #435: Don't Stop Believing…A Vaccine can Work for RSV first appeared on The Skeptics Guide to Emergency Medicine.

El MINSAL decretó Alerta Sanitaria para Chile, debido al aumento de enfermedades respiratorias. El pediatra del Hospital Clínico de la U. de Chile, Guillermo Zepeda, aseguró que con la llegada de Nirsevimab se espera "ver menos pacientes que se hospitalizan".

Matías del Río y Josefina Ríos conversaron con el senador y presidente de la UDI, Javier Macaya, explicó las razones por las que decidieron elegir a José García Ruminot (RN) como nuevo presidente del Senado, pese a la existencia de un compromiso por elegir a Pedro Araya (PPD). Además, comentaron con el Dr. Miguel O'Ryan, decano de la Facultad de Medicina U de Chile la llegada del primer cargamento de Nirsevimab.

Nuestro país es el primero en Latinoamérica en adquirir el medicamento Nirsevimab para enfrentar el virus respiratorio sincicial. ¿Qué sabemos de este medicamento? Leonardo Basso, director del Instituto de Sistemas Complejos de Ingeniería y académico de la U. de Chile nos explicó.

In his weekly clinical update, Dr. Griffin discusses the use of monoclonal antibody therapy to prevent RSV hospitalization of infants and use of GSK's RSV vaccine Arexy to prevent severe disease following RSV infection in adults between 50-59 years before he reviews recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus, including all circulating variants in the US, discusses if how the influenza vaccine is manufactured can reprogram the antibody response, cardiovascular consequences of influenza infection, mortality of chikungunya virus infection, if an alternative vaccination schedule impacts the anti-SARS-CoV-2 immune response, dispels the myth that increased mortality correlated with the first vaccine dose, continues to dispel the myth of viral rebound, how to pay for paxlovid, when to use steroids and the benefits of convalescent plasma, how manage long COVID including prevent burnout and compassion fatigue of caring for long COVID patients, whether the CDC or WHO definition of long COVID is beneficial or the use of directed questions, baselines test and listening to the patient tell their story are beneficial in making a long COVID diagnosis. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Nirsevimab immunoprophylaxis to prevent RSV hospitalization (Eurosurveillance.) Arexvy given Priority Review in US for the prevention of RSV disease in adults aged 50-59 (GSK) Respiratory  disease surveillance (CDC) RSV surveillance  (CDC) RSV national trend (CDC) Can antibodies be redirected from egg adapted epitopes using recombinant or cell cultured based influenza vaccines (Nat) Can influenza infection lead to cardiovascular events (JID) Risk of death after chikungunya infection and disease (Lancet) Influenza/flu surveillance (CDC) Influenza/flu map (CDC) COVID-19  hospital admissions (CDC) COVID-19 national trend (CDC) COVID-19 wastewater testing (biobot) Variant tracker (CDC)  Variant hospital admissions (CDC) Alternative intervals between vaccine doses (Nat Comm)  Early mortality after first vaccination dose (CID) CDC Quarantine guidelines (CDC) To rebound or to not rebound (MMWR) Know your COVID-19 tools (ESMED)  How to pay for Paxlovid (PAXCESS)  Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (IDSociety) Steroids, dexamethasone at the right time (OFID) Anticoagulation guidelines (hematology.org) Burnout compassion fatigue Long COVID (OFID)  Scoring PASC (JAMA)  What is your definition of the Long COVID (WHO) Contribute to our ASTMH fundraiser at PWB Letters read on TWiV 1088 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

Chile se convertirá en el primer país en latinoamérica en adquirir "Nirsevimab", medicamento para inmunizar contra el virus sincicial. De hecho, se anunció que se administrará este medicamento a lactantes de hasta seis meses. Para hablar de este tema y de la ley corta de Isapres nos acompañó la ministra de salud, Ximena Aguilera.

Kimberly James, PharmD shares developments on respiratory syncytial virus (RSV) prevention in infants. For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes. You can also connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Nirsevimab is the new FDA-approved monoclonal antibody RSV vaccine for the prevention of severe lower respiratory illness in infants. In this episode, we discuss the current recommendations on who gets the vaccine and when, how to use a lens of health equity to approach the current vaccine shortages, and how to discuss safety and efficacy with vaccine hesitant parents. Now that nirsevimab is on the routine infant immunization schedule, it's extremely important and pediatric providers understand the recommendations and science behind the monoclonal antibody to help vaccine acceptance that will undoubtedly reduce bronchiolitis hospitalization. Instagram: @thepedsnppodcast Show notes and references thepedsnp.com Disclaimer   References: CDC Health Alert Network. (2023). Limited availability of nirsevimab in the United States—Interim CDC recommendations to protect infants from Respiratory Syncytial Virus (RSV) during the 2023–2024 respiratory virus season. Emergency Preparedness and Response. https://emergency.cdc.gov/han/2023/han00499.asp?c Centers for Disease Control and Prevention. (2023). Frequently asked questions about RSV immunization with monoclonal antibody for children 19 months and younger. Vaccines and Preventable Diseases. https://www.cdc.gov/vaccines/vpd/rsv/hcp/child-faqs.html Centers for Disease Control and Prevention. (2022). Vaccines for Children Program. https://www.cdc.gov/vaccines/programs/vfc/index.html Centers for Disease Control and Prevention. (2023). General best practice guidelines for immunization. Vaccine Recommendations and the Guidelines of the ACIP. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html Jones, J. M., Fleming-Dutra, K. E., Prill, M. M., Roper, L. E., Brooks, O., Sánchez, P. J., Kotton, C. N., Mahon, B. E., Meyer, S., Long, S. S., & McMorrow, M. L. (2023). Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR. Morbidity and mortality weekly report, 72(34), 920–925. https://doi.org/10.15585/mmwr.mm7234a4 Hill, D., & Parga-Belinkie, J. (Host). (2023, August 29). Immunizations special: RSV, Covid, pneumococcal disease, influenza (No. 170) [Audio podcast episode]. In Pediatrics on call. American Academy of Pediatrics. www.aap.org/podcast Rha, B., Curns, A. T., Lively, J. Y., Campbell, A. P., Englund, J. A., Boom, J. A., Azimi, P. H., Weinberg, G. A., Staat, M. A., Selvarangan, R., Halasa, N. B., McNeal, M. M., Klein, E. J., Harrison, C. J., Williams, J. V., Szilagyi, P. G., Singer, M. N., Sahni, L. C., Figueroa-Downing, D., McDaniel, D., … Gerber, S. I. (2020). Respiratory Syncytial Virus-Associated Hospitalizations Among Young Children: 2015-2016. Pediatrics, 146(1), e20193611. https://doi.org/10.1542/peds.2019-3611 Suh, M., Movva, N., Jiang, X., Bylsma, L. C., Reichert, H., Fryzek, J. P., & Nelson, C. B. (2022). Respiratory Syncytial Virus Is the Leading Cause of United States Infant Hospitalizations, 2009-2019: A Study of the National (Nationwide) Inpatient Sample. The Journal of infectious diseases, 226(Suppl 2), S154–S163. https://doi.org/10.1093/infdis/jiac120

Este podcast está presentado por los médicos neonatólogos Dani de Luis Rosell, Elena Itriago, Carolina Michel y Juliana Castellanos; nuestras futuras doctoras Valentina Giraldo y Laura Molina y su anfitriona Maria Flores Cordova, médico residente de pediatría. No dudes en enviarnos preguntas, comentarios o sugerencias a nuestro correo electrónico: nicupodcast@gmail.comLos artículos que se tratan en el episodio de hoy están listados aquí: Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.Hundscheid T, Onland W, Kooi EMW, Vijlbrief DC, de Vries WB, Dijkman KP, van Kaam AH, Villamor E, Kroon AA, Visser R, Mulder-de Tollenaer SM, De Bisschop B, Dijk PH, Avino D, Hocq C, Zecic A, Meeus M, de Baat T, Derriks F, Henriksen TB, Kyng KJ, Donders R, Nuytemans DHGM, Van Overmeire B, Mulder AL, de Boode WP; BeNeDuctus Trial Investigators.N Engl J Med. 2023 Mar 16;388(11):980-990. doi: 10.1056/NEJMoa2207418. Epub 2022 Dec 6.Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, Wählby Hamrén U, Mankad VS, Ren P, Takas T, Abram ME, Leach A, Griffin MP, Villafana T; MELODY Study Group.N Engl J Med. 2022 Mar 3;386(9):837-846. doi: 10.1056/NEJMoa2110275.Antenatal dexamethasone for late preterm birth: A multi-centre, two-arm, parallel, double-blind, placebo-controlled, randomized trial.WHO ACTION Trials Collaborators.EClinicalMedicine. 2022 Feb 12;44:101285. doi: 10.1016/j.eclinm.2022.101285. eCollection 2022 Feb.Trial of Erythropoietin for Hypoxic-Ischemic Encephalopathy in Newborns.Wu YW, Comstock BA, Gonzalez FF, Mayock DE, Goodman AM, Maitre NL, Chang T, Van Meurs KP, Lampland AL, Bendel-Stenzel E, Mathur AM, Wu TW, Riley D, Mietzsch U, Chalak L, Flibotte J, Weitkamp JH, Ahmad KA, Yanowitz TD, Baserga M, Poindexter BB, Rogers EE, Lowe JR, Kuban KCK, O'Shea TM, Wisnowski JL, McKinstry RC, Bluml S, Bonifacio S, Benninger KL, Rao R, Smyser CD, Sokol GM, Merhar S, Schreiber MD, Glass HC, Heagerty PJ, Juul SE; HEAL Consortium.N Engl J Med. 2022 Jul 14;387(2):148-159. doi: 10.1056/NEJMoa2119660. Bienvenidos a La Incubadora: una conversación sobre neonatología y medicina basada en evidencia. Nuestros episodios ofrecen la dosis ideal (en mg/kg) de los más recientes avances para el neonato y para las increíbles personas que forman parte de la medicina neonatal. Soy tu host, Maria Flores Cordova, MD. Presentado por los Neonatólogos Elena Itriago MD, Dani de Luis Rosell MD, Carolina Michel MD, las futuras doctoras Marla Fortoul, Valentina Giraldo, Laura Molina. Creado originalmente por Ben Courchia MD y Daphna Yasova Barbeau MD http://www.the-incubator.org

The McCullough Report with Dr. Peter McCullough – As ambient aerosolized RSV virions are present in hospitals, clinics, and homes, the monoclonal antibody may backfire and enable the inhaled virion to gain access to the bronchial epithelial lining and cause worse bronchiolitis than the baby would have with their own developing natural immunity. This would explain why the efficacy for RSV hospitalization was NOT compelling from the two RCTs of Nirsevimab...

The McCullough Report with Dr. Peter McCullough – As ambient aerosolized RSV virions are present in hospitals, clinics, and homes, the monoclonal antibody may backfire and enable the inhaled virion to gain access to the bronchial epithelial lining and cause worse bronchiolitis than the baby would have with their own developing natural immunity. This would explain why the efficacy for RSV hospitalization was NOT compelling from the two RCTs of Nirsevimab...

RSV infections are not new and have devastating impacts. The recent advent of new prevention strategies has renewed the focus on the disease with a hopeful outlook. For the last 25 years, the only FDA approved product preventing RSV, lower respiratory tract disease, was palivizumab or Synagis, a monoclonal antibody indicated for use in high risk infants children and administered intramuscularly monthly throughout the RSV season. In May, the first ever RSV vaccines were approved, Arexvy and Abrysvo. These two new RSV vaccines were approved for use in adults greater than or equal to 60 years of age. In August this year, one of the RSV vaccines, Abrysvo, also received approval for expanded use for maternal vaccination to prevent RSV lower respiratory tract disease in infants. Nirsevimab or Beyfortus, a new long-acting monoclonal antibody, was approved in July for prevention of RSV lower respiratory tract disease in infants and children. Compared with palivizumab, nirsevimab is indicated for a much broader patient population including recommended use in all infants less than eight months of age, born during or entering their first RSV season. The rollout of nirsevimab has proved challenging due to supply shortages, among other factors. Today we discuss the new RSV prevention strategies, focusing on the pediatric patient population, as well as the recent shortages with nirsevimab. Dr. Deb Bondi, Dr. Nikolai Dahl, as well as Dr. Kyle Hoelting from Vizient join guest host Vizient's John Schoen for today's podcast.   Guest speakers:  Deb Bondi, PharmD, FCCP, BCPS, BCPPS Pediatric Clinical Coordinator, NICU Clinical Pharmacy Specialist, and PGY2 Pediatric Pharmacy Residency Program Director UChicago Medicine, Comer Children's Hospital   Nikolai Dahl, PharmD Utilization and Formulary Program Manager John Muir Health   Kyle Hoelting, PharmD, BCPS Senior Clinical Manager of Drug Shortages and Drug Information Vizient Center for Pharmacy Practice Excellence    Host:  John Schoen, PharmD, BCPS  Senior Clinical Manager of Evidence-Based Medicine and Drug Information Vizient Center for Pharmacy Practice Excellence   Show Notes:  [02:39-04:09] Update on where everything currently stands with the Nirsevimab supply and what led to the shortage [04:10-05:01] Information on whether or not there's going to be additional supply of either the 50 mg or 100 mg syringes later this season [05:02-06:01] Resources related to mitigating this nirsevimab shortages [06:02-10:29] What University of Chicago and John Muir Health are doing with these new RSV vaccines and the new monoclonal antibody, Beyfortus [10:30-13:15] Formulary decisions University of Chicago and John Muir Health make around nirsevimab and palivizumab [13:16-15:24] Organizational preference for the maternal RSV vaccine or nirsevimab [15:25-20:33] Other logistical issues with either nirsevimab or the maternal RSV vaccines, such us scope of practice consideration, stocking of the VFC product in patient education, et cetera [20:34-22:01] Payment of billing issues either University of Chicago or John Muir Health experienced for either nirsevimab or the maternal RSV vaccine [22:02-24:57] Clinical pearls or advice related to these new prevention strategies   Links | Resources: Vizient member RSV resources RSV vaccines in adults side-by-side comparison RSV monoclonal antibodies in pediatrics side-by-side comparison FAQ pediatric RSV prevention strategies Minute Market Insight on nirsevimab shortage Mitigation strategy on nirsevimab shortage   Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Android RSS Feed

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-353 Overview: Bronchiolitis caused by respiratory syncytial virus (RSV) infection in infants is common and can lead to hospitalization if severe. There are now 2 ways to prevent this: immunizing the mother during pregnancy or giving monoclonal antibodies. Listen in as we discuss the recommendations for RSV prevention and how to best incorporate them into your practice. Episode resource links: Fleming-Dutra KE, Jones JM, Roper LE, et al. Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep 2023;72:1115–1122. Jones JM, Fleming-Dutra KE, Prill MM, et al. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep 2023;72:920–925 Kampmann B, Madhi SA, Munjal I, et al. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med. 2023;388(16):1451-1464. Guest: Alan M. Ehrlich MD, FAAFP   Music Credit: Richard Onorato

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-353 Overview: Bronchiolitis caused by respiratory syncytial virus (RSV) infection in infants is common and can lead to hospitalization if severe. There are now 2 ways to prevent this: immunizing the mother during pregnancy or giving monoclonal antibodies. Listen in as we discuss the recommendations for RSV prevention and how to best incorporate them into your practice. Episode resource links: Fleming-Dutra KE, Jones JM, Roper LE, et al. Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep 2023;72:1115–1122. Jones JM, Fleming-Dutra KE, Prill MM, et al. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep 2023;72:920–925 Kampmann B, Madhi SA, Munjal I, et al. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med. 2023;388(16):1451-1464. Guest: Alan M. Ehrlich MD, FAAFP   Music Credit: Richard Onorato

Is there an association between serotonin levels and long COVID? Find out about this and more in today's PV Roundup podcast.

Today's episode features Dr Michael Hochman,to discuss the newly approved FDA product to prevent RSV in children, Nirsevimab (sold under the brand name Beyfortus). Recently there have been two RSV vaccines approved for adults—one for individuals over 60 years old, and one for use in pregnancy to prevent RSV in infants.  On today's podcast, the conversation will focus on  Nirsevimab, a shot that has been approved by the FDA for all babies up to 8 months old and  a second shot for infants up to 19 months who are considered to be at high risk of severe RSV infection.   Nirsevimab is a monoclonal antibody with activity againast respiratory syncytial virus (RSV).  On today's podcast we will review the benefits and potential side effects of Nirsevimab.Dr Michael Hochman is a Harvard Medical School graduate,  a Robert Wood Johnson Clinical Scholars Fellow at UCLA where he received his masters in public health, and he is the founding editor of a book series called “ 50 studies every doctor should know”, so he has a keen interest in reviewing medical studies.  Get matched with a therapist by using Better Help! Give it a try---invest in your mental health: https://betterhelp.com/askdrjessica for 10% off your first month of therapy. Thank you to Better Help for supporting the Ask Dr Jessica podcast.Dr Jessica Hochman is a board certified pediatrician, mom to three children, and she is very passionate about the health and well being of children. Most of her educational videos are targeted towards general pediatric topics and presented in an easy to understand manner. Do you have a future topic you'd like Dr Jessica Hochman to discuss? Email Dr Jessica Hochman askdrjessicamd@gmail.com. Dr Jessica Hochman is also on social media:Follow her on Instagram: @AskDrJessicaSubscribe to her YouTube channel! Ask Dr JessicaSubscribe to this podcast: Ask Dr JessicaSubscribe to her mailing list: www.askdrjessicamd.comThe information presented in Ask Dr Jessica is for general educational purposes only. She does not diagnose medical conditions or formulate treatment plans for specific individuals. If you have a concern about your child's health, be sure to call your child's health care provider.

With cases of Respiratory Syncytial Virus (RSV) on the rise this fall, Dr. Barbara Taylor, professor of infectious diseases at UT Health San Antonio, joins us for this timely episode all about RSV. Importantly, she covers the unprecedented events of the 2022-2023 season that was marred by a ‘tripledemic' of respiratory diseases.  How do the lessons learned change the preventive approach to better protect against the deadly infection?   Episode Highlights 0:16 Intro 0:48 The burden of RSV today 2:11 Transmission, presentation and diagnosis of RSV 4:33 Likelihood of an RSV, COVID-19, flu “triple-demic” 7:35 The history of RSV vaccine development 12:09 Risk of RSV mutation and variants 14:19 The new RSV vaccines 20:09 Spacing the RSV vaccine with other seasonal shots 22:14 Age and comorbidities as vaccine criteria 24:30 In vitro immunization 27:39 Nirsevimab and monoclonal antibodies for RSV 29:31 Using the full toolset against RSV 31:50 Yearly COVID-19 vaccine updates? 33:24 A universal flu vaccine? 37:20 Outro Want more Lungcast? Visit us at HCPLive.com/podcasts/lungcast or www.lung.org/professional-education/lungcast

For the first time, a preventative medicine is available to protect infants and high-risk toddlers from respiratory syncytial virus (RSV). Lori Handy, MD, MSCE, attending physician in the Division of Infectious Diseases at Children's Hospital of Philadelphia, details the science behind the monoclonal antibody, nirsevimab (Beyfortus) and its importance, safety and efficacy, side effects, administration and proven benefits, such as a decrease in morbidity, as shown by clinical trials; and more. This podcast is for general informational and educational purposes only and is not to be considered as medical advice for any particular patient. Clinicians must rely on their own informed clinical judgment in making recommendations to their patients. ©2023 by Children's Hospital of Philadelphia, all rights reserved.

  Practitioners Click here for free credit: https://cmetracker.net/UTHSCSA/Publisher?page=pubOpen#/getCertificate/10094952 Update on RSV Prevention in Infants FACULTY: Michael Odom, MD is a neonatologist with UT Health San Antonio and University Hospital.  He's passionate researching methods to prevent RSV in babies and has been doing so since the 1990's.   OVERVIEW: Pediatrics Now Host and Executive Producer Holly Wayment discusses with Dr. Odom cutting edge RSV prevention, including the now recommended Nirsevimab.   Dr. Odom answers questions from pediatric practitioners. www.pediatricsnowpodcast.com   DISCLOSURES: Michael Odom, MD has no financial relationships with ineligible companies to disclose.   The Pediatric Grand Rounds Planning Committee (Deepak Kamat, MD, PhD, Steven Seidner, MD, Daniel Ranch, MD, and Elizabeth Hanson, MD) has no financial relationships with ineligible companies to disclose.    The UT Health Science Center San Antonio and Deepak Kamat, MD course director and content reviewer for the activity, have reviewed all financial disclosure information for all speakers, facilitators, and planning committee members; and determined and resolved all conflicts of interests.   CONTINUING MEDICAL EDUCATION STATEMENTS: The UT Health Science Center San Antonio is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.   The UT Health Science Center San Antonio designates this live activity up to a maximum of 0.50 AMAPRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.   CREDITS: AMA PRA Category 1 Credits™ (0.50) Non-Physician Participation Credit (0.50)    

Pediatrician Dr. Jill Schaffeld consults Dr. Bob Frenck on recent movement in pediatric immunizations - Niresvimab (Beyfortus) for RSV, single dose Covid-19 vaccinations, and Prevnar-20.  Episode recorded on August 17, 2023.  

TWiV reviews approvals of the first gene therapy for severe hemophilia A in adults and a monoclonal antibody to prevent RSV respiratory disease in babies and toddlers, and a common allele of HLA that mediates asymptomatic SARS-CoV-2 infection through pre-existing T cell immunity due to previous exposure to common cold coronaviruses. Hosts: Vincent Racaniello, Dickson Despommier, Alan Dove, Kathy Spindler, and Brianne Barker Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode MicrobeTV Discord Server First gene therapy for hemophilia A approved (FDA) Luxurna, gene therapy for vision loss (FDA) Anti-RSV monoclonal antibody approved (FDA) Trial of single-dose Nirsevimab (NEJM) Letters read on TWiV 1028 Timestamps by Jolene. Thanks! Weekly Picks Dickson – Phoenix hits 110 degrees for the 19th day in a row, setting national record Brianne – James Webb Telescope One Year Anniversary Photo Kathy – Drone awards photos Alan – WHO Film Festival winners Vincent – Thinking, Fast and Slow by Daniel Kahneman Listener Picks David – The Mass Extinction Debates: A Science Communication Odyssey Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv

In this episode, Helen Y. Chu, MD, MPH, shares updates on RSV vaccines, including:An overview of vaccine candidates under investigationRecently FDA-approved RSV vaccines for older adultsConsiderations for the next respiratory viral seasonCoadministration of RSV vaccines with other respiratory viral vaccines (eg, influenza, SARS-CoV-2)Target populations for RSV vaccinationRSV prevention in infants with the maternal vaccine and monoclonalFaculty:Helen Y. Chu, MD, MPHAssociate Professor of MedicineDivision of Allergy & Infectious DiseasesUniversity of Washington School of MedicineSeattle, WashingtonLink to full program: https://bit.ly/3nb25xehttps://bit.ly/3nb25xeLink to downloadable slides: https://bit.ly/3TsXym5

This episode covers the latest FDA approvals from Jun 5 to Jun 9, 2023. Here are the key highlights: PREVYMIS (letermovir) has been approved by the FDA to prevent cytomegalovirus (CMV) disease in high-risk adult kidney transplant recipients, based on a phase 3 trial where it was found to be superior to valganciclovir in reducing the incidence of CMV disease after kidney transplantation. Vevye (cyclosporine ophthalmic solution) has received FDA approval as the first waterless cyclosporine-based solution for dry eye disease, showing significant reduction in dry eye disease activity compared to placebo and another cyclosporine product in clinical trials. An FDA advisory panel has expressed support for traditional US regulatory approval of Leqembi (lecanemab-irmb), a new Alzheimer's drug manufactured by Eisai and Biogen, which has shown promising results in slowing cognitive decline in patients with early Alzheimer's disease. A decision for traditional approval is expected in July. The FDA's Antimicrobial Drugs Advisory Committee has voted in favor of the safety and efficacy of nirsevimab, a monoclonal antibody, in protecting against respiratory syncytial virus (RSV)-associated lower respiratory disease in infants. Approval decision is anticipated in the third quarter of this year. Restylane Eyelight, a hyaluronic acid dermal filler manufactured by Galderma, has been FDA-approved for the treatment of undereye hollows in adults over the age of 21, based on positive results from a Phase 3 study evaluating its efficacy and safety in correcting volume loss under the eyes. Listen to all the episodes here.  Brought to you by Nascentmc.com. A group of MD- and PhD-level medical writers serving the continuing medical education industry and meeting medical writing deadlines with excellence and enthusiasm.  Intro and outro musicGarden Of Love by Pk jazz Collective  

Epidemiologische Daten von RSV assoziierten Hospitalisierungen der vergangenen sieben Saisons haben eine Gruppe von Medizinern aus der Steiermark zusammengetragen. 976 Kinder, die meisten waren unter einem Jahr alt, wurden in den vergangenen Jahren ins Spital eingeliefert, wobei die Zahl der Hospitalisierungen über die Jahre stark zugenommen hat. Das sagt Dr. Gülsen Sever Yildiz von der Universitätsklinik für Kinder- und Jugendheilkunde in Graz. Sie ist eine der Autorinnen der Southern Austria RSV Inpatient Investigation-Studie, kurz: ARNI. Zwar gibt es nach wie vor keine kausale RVS-Therapie, aber eine neue Prophylaxe, die nur noch einmal pro Saison verabreicht werden muss. Über diesen monoklonalen Antikörper, Nirsevimab, berichtet Dr. Sever Yildiz, aber auch über die Gründe für die jüngste RSV-Welle und den Zustand der jungen, zumeist männlichen Patienten. Die Fragen stellt Martin Burger.

Click HERE for FREE CREDIT: https://cmetracker.net/UTHSCSA/Publisher?page=pubOpen#/getCertificate/10092420   If you're a practitioner, click here for free credit: https://bit.ly/3Y6PlG8 FACULTYMichael Odom is a neonatologist with UT Health San Antonio and University Hospital.  He is passionate researching methods to prevent RSV in babies.OVERVIEWPediatrics Now host Holly Wayment discusses with Dr. Odom cutting edge RSV prevention during this unprecedented RSV Season.   Holly  and Dr. Odom discuss new methods on the horizon, including a study where your patient would have a 2/3 chance in getting the RSV antibody being tested.  Since the recent recording of this Podcast, Nirsevimab , discussed here, was approved in Europe to prevent RSV.DISCLOSURESMichael Odom,  MD, has no financial relationships with ineligible companies to disclose. The Pediatric Grand Rounds Planning Committee (Deepak Kamat, MD, PhD, Daniel Ranch, MD and Elizabeth Hanson, MD) has no financial relationships with ineligible companies to disclose.  Planning Committee member Steven Seidner, MD has disclosed he receives funding from Draeger Medical for the Clinical Study to Evaluate the Safety and Effectiveness of the Infinity Acute Care System Workstation Neonatal Care Babylog VN500 Device in High-Frequency Oscillatory Ventilation (HFOV) Mode in Extremely Low Birth Weight (ELBW) Neonates for which he is a co-principal investigator. The relevant financial relationships noted for Dr. Seidner have been mitigated.  The UT Health Science Center San Antonio and Deepak Kamat, MD course director and content reviewer for the activity, have reviewed all financial disclosure information for all speakers, facilitators, and planning committee members; and determined and resolved all conflicts of interests.CONTINUING EDUCATION STATEMENTSThe UT Health Science Center San Antonio is accredited by the Accreditation Council for Continuing Medical Education to provide continuing education for physicians.  The UT Health Science Center San Antonio designates this live activity up to a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Commission has authorized the world's first one-dose drug against a respiratory virus that sickens millions of babies and children globally every year. In a statement, drugmakers Sanofi and AstraZeneca said the European Commission had given the green light to nirsevimab, a laboratory-developed antibody designed to protect infants during their first exposure to RSV, or respiratory syncytial virus, a highly contagious common infection that infects nearly all babies by age 2. At the moment, babies at high risk of the disease can be given monthly shots to protect them during RSV season. In September, the European Medicines Agency recommended that nirsevimab, sold as Beyfortus, be authorized based on advanced research that showed the drug reduced the chances that babies with RSV needed medical attention and appeared to be safe, compared to infants who got a dummy treatment. The drug is given in a single injection. “We are excited about the opportunity to expand prevention efforts to all infants,” said Silke Mader, co-founder of the European Foundation for the Care of Newborn Infants. In the U.S., RSV is causing an early surge of infections in children's hospitals this year. European health officials are warning there could be a similar spike across the continent. For most healthy people, RSV is a cold-like nuisance. But the virus can be life-threatening for the very young and the elderly. The virus can infect deep in the lungs and in small babies, it can impede breathing by inflaming their tiny airways. RSV kills about 100,000 babies annually, mostly in developing countries. Nirsevimab was developed to give newborns and infants immediate protection against RSV through an antibody to prevent infections in their respiratory systems. In November, Pfizer announced preliminary research showing that a new vaccine given to pregnant women could help protect their babies against RSV, after decades of failure to develop an effective shot. This article was provided by The Associated Press.

  Vidcast:  https://youtu.be/oh_JQiPfRDM   I told you about an RSV vaccine for prospective moms that protects their newborn infants.  Now AstraZeneca and Sanofi have partnered to create, test, and market a drug that squelches newborn RSV infections after they occur.  The new pharmaceutical, the monoclonal antibody nirsevimab, blocks RSV's fusion protein so that the virus cannot enter human cells and replicate.  Branded as Beyfortus, the antibody has a long life that permits it last the entire RSV season and protect for the first 6 months of life.  The drug has received marketing authorization from the European Commission and will likely receive the same from the FDA and CDC.   https://medcitynews.com/2022/11/astrazeneca-sanofi-win-european-nod-for-rsv-preventing-drug-for-infants/   #rsv #monoclonal #antibody #nirsevimab #beyfortus #europeanunion  

What do you know about the new "stealth" COVID-19 variant? Find out about this and more in today's PV Roundup podcast.